MeiraGTx Holdings plc Board of Directors

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Dr. Alexandria Forbes Ph.D.

Dr. Alexandria Forbes Ph.D.

CEO, President & Director

Dr. Alastair Leighton Ph.D.

Dr. Alastair Leighton Ph.D.

Senior Vice President of Manufacturing & Supply Chain

Ms. Christine Elise Sheehy

Ms. Christine Elise Sheehy

Senior Vice President of Global Integration

Dr. Stuart Naylor Ph.D.

Dr. Stuart Naylor Ph.D.

Chief Development Officer

Mr. Robert J. Wollin J.D.

Mr. Robert J. Wollin J.D.

General Counsel & Secretary

Mr. Tim Randall

Mr. Tim Randall

Senior Vice President of Risk & Internal Controls

Dr. Michel Michaelides M.D.

Dr. Michel Michaelides M.D.

Head of Clinical Ophthalmology

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.